CASI Pharmaceuticals – executive interview – from EDISON
1,900
25
2023-5-12 15:30
CASI Pharmaceuticals & BioInvent
好好的告个别吧~
手术无菌技术
桡骨创伤入路A部分
Total laparoscopic hysterectomy
骨关节炎
腰椎椎间关节经椎板螺丝钉固定
肝门胆管癌切除术(86例切除经验 1983-1993)
0 bullet chats
Please Sign In first
Unauthorized reproduction is prohibited
CASI Pharmaceuticals is focused on building a portfolio of drugs which it intends to produce for Chinese and worldwide markets. Its products are focused on the hematology and oncology space, including its first product, Evomela, launched in China in 2019. The company is also developing an anti-CD19 CAR-T therapy, CNCT19, and the anti-CD38 drug CID-103, among others. The goal is to seek approval through new pathways that have opened in the quickly changing Chinese regulatory environment.
Comments 0
Please to post a comment~
Loading...
Related Suggestion